Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (8241)	9/16/2000 10:19:04 PM
From: Vector1	Read Replies (1) \| Respond to of 9719

Biogen took anti-CD40 into the clinic. So far they suspended their phase IIs as a result of clotting problems> V1

To: scaram(o)uche who wrote (8241)	9/17/2000 6:46:12 PM
From: Mark Bong	Respond to of 9719

Richard, I will take a stab at it. I think that IDEC has anti-CD40 in a trial. It is known as clenoliximab. (Idec-151 ) It is in trials for rheumatoid arthritis. See the September 1 issue of GEN (Genetic Engineering News), page 98.

To: scaram(o)uche who wrote (8241)	9/18/2000 12:21:04 AM
From: Don Miller	Read Replies (1) \| Respond to of 9719

FYI, Richard Thanks all for the replies. A little about Tanox CD40 work will be found in the bottom paragraph. Before the phase III started some MDs' on the SEPR thought E25 effect did not last more than about 6 months. Since posting here the first time I have received one unsubstantiated response that Novartis pulled out Friday, for yet unexplained reasons. I can not find a news release to that effect, or even the BLA submission date. I have been told the two monkeys were killed in the clinical trial of E26, not E25, so why pull out now? Also another link to AHH extranet.ahh.com From tanox.com in the product development page. "Tanox Pharma, B.V. is developing a unique monoclonal antibody that inhibits the CD40 pathway, a major immuno-regulatory pathway controlling antibody and cellular immune responses."